Starpharma (ASX:SPL) share price lifts on supply and distribution deal

The company’s shares are rebounding from yesterday’s 52-week low.
The post Starpharma (ASX:SPL) share price lifts on supply and distribution deal appeared first on The Motley Fool Australia. –

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher today following an update from the biopharmaceutical company.

At the time of writing, the dendrimer products developer’s shares are up 3.70% to $1.12.

What did Starpharma announce?

According to its release, Starpharma announced it has signed an initial supply contract for Viraleze in Vietnam.

Viraleze is an antiviral nasal spray that has been shown in laboratory studies to inactivate a broad spectrum of respiratory/cold viruses. This includes multiple variants of SARS-CoV-2 (COVID-19), influenza, RSV, SARS, and MERS (Middle East Respiratory Syndrome).

The first orders of around 100,000 units of Viraleze are expected to arrive in Vietnam sometime in early November. Launch preparations for the product are anticipated to commence shortly. A portion of these orders will also be donated to hospitals and other healthcare organisations across the country.

Vietnam with a population of about 97 million, is currently experiencing a significant Delta outbreak despite 20% of its population being fully vaccinated. According to the World Health Organisation (WHO), the COVID-19 has taken 21,000 lives in Vietnam so far.

Starpharma noted that registration for the product is well advanced in the south-east Asian country. Once completed, an ongoing distribution agreement is expected to follow involving much larger orders of Viraleze. These arrangements are exclusive for retail, pharmacies, clinics, and hospitals in Vietnam.

Starpharma CEO, Dr Jackie Fairley commented:

We are very pleased to be able to make Viraleze available to Vietnamese consumers and frontline workers next month, especially given the current Delta outbreak and vaccination rates in Vietnam. This supply contract is one of a number of international commercial arrangements for Viraleze being negotiated by Starpharma and we look forward to making further announcements about those soon.

Starpharma share price snapshot

At the start of 2021, Starpharma shares rocketed to an all-time high of $2.52 in mid-February. However, the sharp rise quickly came, and then its shares crashed down the following month.

Since then, the company’s shares have continued their downward trend, hitting a 52-week low of $1.04 just yesterday.

Starpharma is down by more than 20% in the past 12 months, and almost 30% lower in 2021.

The post Starpharma (ASX:SPL) share price lifts on supply and distribution deal appeared first on The Motley Fool Australia.

Should you invest $1,000 in Starpharma right now?

Before you consider Starpharma, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Starpharma wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why Fletcher Building, Magellan, Sezzle, & Starpharma are racing higher

Here’s why the Starpharma (ASX:SPL) share price is charging 4% higher today

These were the best performing ASX biotech shares in September

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!